- Home
- AKBA vs UWMC Comparison
AKBA vs UWMC Comparison
Compare AKBA & UWMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- UWMC
- Stock Information
- Founded
- AKBA 2007
- UWMC 1986
- Country
- AKBA United States
- UWMC United States
- Employees
- AKBA N/A
- UWMC N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- UWMC Finance: Consumer Services
- Sector
- AKBA Health Care
- UWMC Finance
- Exchange
- AKBA Nasdaq
- UWMC Nasdaq
- Market Cap
- AKBA 958.6M
- UWMC 825.8M
- IPO Year
- AKBA 2014
- UWMC N/A
- Fundamental
- Price
- AKBA $3.97
- UWMC $4.25
- Analyst Decision
- AKBA Strong Buy
- UWMC Buy
- Analyst Count
- AKBA 5
- UWMC 8
- Target Price
- AKBA $6.90
- UWMC $6.46
- AVG Volume (30 Days)
- AKBA 5.0M
- UWMC 7.4M
- Earning Date
- AKBA 08-07-2025
- UWMC 08-05-2025
- Dividend Yield
- AKBA N/A
- UWMC 9.39%
- EPS Growth
- AKBA N/A
- UWMC N/A
- EPS
- AKBA N/A
- UWMC N/A
- Revenue
- AKBA $184,909,000.00
- UWMC $2,486,541,000.00
- Revenue This Year
- AKBA $26.88
- UWMC $11.32
- Revenue Next Year
- AKBA $44.34
- UWMC $22.84
- P/E Ratio
- AKBA N/A
- UWMC N/A
- Revenue Growth
- AKBA N/A
- UWMC 10.39
- 52 Week Low
- AKBA $0.93
- UWMC $3.80
- 52 Week High
- AKBA $4.08
- UWMC $9.74
- Technical
- Relative Strength Index (RSI)
- AKBA 62.71
- UWMC 52.67
- Support Level
- AKBA $3.48
- UWMC $3.98
- Resistance Level
- AKBA $3.77
- UWMC $4.40
- Average True Range (ATR)
- AKBA 0.17
- UWMC 0.16
- MACD
- AKBA -0.04
- UWMC 0.01
- Stochastic Oscillator
- AKBA 62.82
- UWMC 79.34
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.